With diseases like COVID-19, monkeypox, and Ebola, the last few years have highlighted the importance of preparedness and response to global infectious diseases. This includes R&D focused on developing products against current or future global health threats and ongoing R&D efforts aim to expand and improve on these vaccines and therapeutics, developing candidates on different platforms and with better, longer-lasting, or expanded efficacy. Such products can be used during health crises in the US or abroad, to protect and treat travelers, address the burden of infectious diseases that affect many people around the world, and protect against future disease threats in the event of their global spread.
Altimmune Announces Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application.
University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate – AdCOVID – that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.
Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced new results from a preclinical study demonstrating the ability of its AdCOVID vaccine candidate to neutralize the rapidly emerging SARS-CoV-2 B.1.351 variant of concern that originated in South Africa. B.1.351 carries multiple mutations in the receptor binding domain (RBD) including the E484K mutation that has been shown to substantially decrease the ability of authorized vaccines to neutralize the virus.
Dr. Vipin Garg, Altimmune’s (ALT) CEO since 2018 and a biotech industry veteran, has successfully led the publicly-traded company through these turbulent pandemic waters. We recently caught up with Dr. Garg to discuss the pandemic, Altimmune’s deep product pipeline, his unique perspectives on the BioHealth Capital Region (BHCR), and the state of the U.S. supply chain and biotech manufacturing ecosystem.
The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.
The Investor Relations website contains information about Altimmune’s business for stockholders, potential investors, and financial analysts.
Altimmune Commences Enrollment In Phase 1 Clinical Trial Of AdCOVID™ — A Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Altimmune Commences Enrollment In Phase 1 Clinical Trial Of AdCOVID™ — A Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate Intranasal administration targets the virus at its point of entry and in a [….]
Covid 19 Timeline Year 2020 *click article titles below to read original BioBuzz content from the past year MARCH 4/7/2020 Coronavirus Pandemic Good News Roundup Sheds Light Amidst Trying COVID-19 [….]
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.